Notice of Establishment, 16169 [06-3096]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 61 / Thursday, March 30, 2006 / Notices
The U.S. Census Bureau website
contains AI/AN specific data at the
Tribal census tract level. Data is
provided at https://factfinder.
census.gov/home/aian/ by
Tribe and language; reservations and
other AI/AN areas; country and Tribal
census tract level; and economic
category.
The Public Health Service (PHS)
strongly encourages all grant and
contract recipients to provide a smokefree workplace and promote the non-use
of all tobacco products. In addition,
Public Law 103–227, the Pro-Children
Act of 1994, prohibits smoking in
certain facilities (or in some cases, any
portion of the facility) in which regular
or routine education, library, day care,
health care or early childhood
development services are provided to
children. This is consistent with the
PHS mission to protect and advance the
physical and mental health of the
American People.
Dated: March 21, 2006.
Robert G. McSwain,
Deputy Director, Indian Health Service.
[FR Doc. 06–3008 Filed 3–29–06; 8:45 am]
BILLING CODE 4165–16–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
cprice-sewell on PROD1PC66 with NOTICES
Notice of Establishment
Pursuant to the Federal Advisory
Committee Act, as amended (5 U.S.C.
Appendix 2), the Director, National
Institutes of Health (NIH), announces
the establishment of the National Cancer
Institute Clinical Trials Advisory
Committee (Committee).
This Committee shall advise the
Director, NCI, NCI Deputy Directors,
and the Director of each NCI Division on
the NCI-support national clinical trials
enterprise to build a strong scientific
infrastructure by bringing together a
broadly developed and engaged
coalition of stakeholders involved in the
clinical trials process.
The Committee will consist of 25
members, including the Chair,
appointed by the Director, NCI.
Members shall be authorities
knowledgeable in the fields of
community, surgical, medical, and
radiation oncology, patient advocacy,
extramural clinical investigation,
regulatory agencies, pharmaceutical
industry, public health, clinical trials
design, management and evaluation,
drug development and developmental
therapeutics, cancer prevention and
VerDate Aug<31>2005
15:32 Mar 29, 2006
Jkt 208001
control research in the fields of interest
to NCI.
Duration of this committee is
continuing unless formally determined
by the Director, NCI that termination
would be in the best public interest.
Dated: March 21, 2006.
Elias A. Zerhouni,
Director, National Institutes of Health.
[FR Doc. 06–3096 Filed 3–29–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Immunogenic Peptides and Methods of
Use for Treating and Preventing Cancer
Jay A. Berzofsky et al. (NCI)
U.S. Provisional Application No. 60/
773,319 filed 03 Nov 2005 (HHS
Reference No. E–312–2005/0–US–01)
Licensing Contact: John Stansberry; 301/
435–5236; stansbej@mail.nih.gov.
Rhabdomyosarcoma is a malignant
(cancerous), soft tissue tumor found in
children. The most common sites are
the structures of the head and neck, the
urogenital tract, and the arms or legs.
The inventors have discovered an
epitope that is created by a
chromosomal translocation that occurs
in about 80% of alveolar
rhabdomyosarcoma and can elicit a
human cytotoxic T lymphocytes (CTL)
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
16169
response in individuals who express
HLA–B7.
Many tumors express mutated tumor
associated antigens that often contain Tlymphocyte epitopes. However, the
immune system often remains incapable
of overtaking the growth potential of the
malignant cells. Previous attempts to
obtain protective and therapeutic antitumor immunity have been moderately
successful (Dagher et al., Med Pediatr
Oncol 38: 158–164 (2002) and Rodeberg
et al., Cancer Immuno Immunother 54:
526–534 (2005)). This present invention
seeks to improve on previous attempts
by providing more immunogenic
peptides that bind to a Major
Histocompatibility Complex (MHC)
Class I molecule with higher affinity,
and fusion proteins comprising at least
one of the inventive immunogenic
peptides. This discovery involves
human T-cell responses to human
tumors.
The National Cancer Institute
welcomes statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
NCI’s technology related to methods of
protective and therapeutic
immunogenic peptides. Please contact
Dr. Patrick Twomey at 301–496–0477 or
twomeyp@mail.nih.gov for more
information.
Impaired Neuregulin1-Stimulated B
Lymphoblast Migration as Diagnostic
for Schizophrenia
Daniel Weinberger et al. (NIMH)
U.S. Provisional Application No. 60/
735,353 filed 10 Nov 2005 (HHS
Reference No. E–181–2005/1–US–01)
Licensing Contact: Norbert Pontzer; 301/
435–5502; pontzern@mail.nih.gov.
Schizophrenia may be a
neurodevelopmental disorder
(Weinberger D.R. and Marenco S. in
Schizophrenia as a neurodevelopmental
disorder, Hirsch S., Weinberger D.R.
(eds) Schizophrenia, 2nd ed., Blackwell
Science: Oxford, UK, 2003 pp 326–348).
Neuregulin1 (NRG1) plays a critical role
in neuronal migration and maturation
by interacting with ErbB tyrosine kinase
receptors and linkage studies and
genetically engineered animals have
implicated NRG1-mediated signaling in
the neuropathogenesis of schizophrenia.
Although no technique is available to
assess NRG1/ErbB mediated neural
migration in living human brain, there
is increasing recognition that neuronal
cells and immune cells share many
cellular and molecular mechanisms for
cell migration and motility. These
inventors showed NRG1 mediated
chemotactic responses of B lymphocytes
from schizophrenic patients are
E:\FR\FM\30MRN1.SGM
30MRN1
]]>Agencies
[Federal Register Volume 71, Number 61 (Thursday, March 30, 2006)]
[Notices]
[Page 16169]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-3096]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Establishment
Pursuant to the Federal Advisory Committee Act, as amended (5
U.S.C. Appendix 2), the Director, National Institutes of Health (NIH),
announces the establishment of the National Cancer Institute Clinical
Trials Advisory Committee (Committee).
This Committee shall advise the Director, NCI, NCI Deputy
Directors, and the Director of each NCI Division on the NCI-support
national clinical trials enterprise to build a strong scientific
infrastructure by bringing together a broadly developed and engaged
coalition of stakeholders involved in the clinical trials process.
The Committee will consist of 25 members, including the Chair,
appointed by the Director, NCI. Members shall be authorities
knowledgeable in the fields of community, surgical, medical, and
radiation oncology, patient advocacy, extramural clinical
investigation, regulatory agencies, pharmaceutical industry, public
health, clinical trials design, management and evaluation, drug
development and developmental therapeutics, cancer prevention and
control research in the fields of interest to NCI.
Duration of this committee is continuing unless formally determined
by the Director, NCI that termination would be in the best public
interest.
Dated: March 21, 2006.
Elias A. Zerhouni,
Director, National Institutes of Health.
[FR Doc. 06-3096 Filed 3-29-06; 8:45 am]
BILLING CODE 4140-01-M
